Foley & Lardner LLP

Automobile Law; Emerging Technologies; Energy; Entertainment Law; Media Law; Food Law; Golf; Resort; Health Care; Insurance; Life Sciences; Nanotechnology; Sports Law; Business Law; Corporate Law; Commercial Transactions; Business Counseling; Corporate Governance Services; Environmental Regulation; Estates; Trusts; Finance; Financial Institutions Law; Health Care Finance; Business Reorganization; International Business Law; Mergers And Acquisitions; Private Equity; Venture Capital; Public Finance Services; Real Estate; Tax Law; Employee Benefits; Individual Planning; Transactional; Securities; Business Transactions; Project; Infrastructure Finance; Asset Securitization; Interference; Financial Products; Variable Insurance; Technology Law; Risk Management; Captives; Public Agencies; Brownfields; Land Use; Entitlement; Airport Services; Agency; Distribution; Hedge Funds; Higher Education Law; Structured Finance; Tenant-In-Common; Directors; Officers; Taxation; Charitable Gifts; Private Foundations; Estate Planning; Water Issues; Wind Energy; Reinsurance Runoff; Surface Transport; Arbitrage Rebate Compliance; Intellectual Property; Biotechnology; Pharmaceutical; Chemical; Consumer Law; Industrial Products; Electronics; Ip Litigation; Trademarks; Copyrights; Advertising Law; Stem Cell Technologies; Genomics; Litigation; Antitrust; Appellate Practice; Bankruptcy; Business Reorganizations; Construction Law; Franchise Law; Energy Regulation; Family Law; General Commercial Litigation; Insurance Dispute Resolution; Labor And Employment; Product Liability; Securities Litigation; Enforcement; Regulation; Valuation; Fiduciary Litigation; White Collar Defense; Corporate Compliance; Mechanical; Electromechanical Technologies; Ip Due Diligence; Business Method Patents; Patent Prosecution; Copyright Enforcement; Health Law; Medical Devices; Nutraceuticals; Provider Operations; Academic Medical Centers; Reinsurance; Commutation; Health Care Compliance; Translational Research; Fda; Hipaa; Long Term Care; Medicare And Medicaid; Information Technology; Outsourcing; Data Security; Privacy Law; Telecommunications Law; Computers And Software Law; Multimedia Law; Government Procurement; Political Law; Public Affairs; Strategic Communications; Lobbying; Investor Relations; Appropriations; Government Relations; State Affairs; Biotech; Biomedical Start-Ups; Clinical Research; Commercial Development; Erisa; False Claims; Compliance Counseling; Financial Markets; Hospital-Physician Joint Ventures; Insolvency; Mixed Use; Retail Development; Physicians; Medical Groups; Residential Real Estate; Condominium Law; Resorts; Senior Living; Syndicated; Securities-Related Transactions; Trade Secret/Noncompete Litigation.

Federal Circuit Holds That Third Party Clinical Trial May Not Constitute Public Use
Courtenay C. Brinckerhoff, June 5, 2013
In Dey, L.P. v. Sunovion Pharmaceuticals, Inc., the Federal Circuit vacated the district court’s grant of summary judgment in favor of Sunovion, and remanded for further consideration of whether Sunovion’s clinical trial constituted a “public use” of the formulation claimed...

Nanomedicine Hitting Its Stride? Beware of Patent Risks
Stephen B. Maebius, June 4, 2013
Though the first nanoparticulate drug formulation was approved by the U.S. FDA way back in 1995, a recent flurry of deals and product approvals have shown increasingly high valuations for nanomedicine companies.

Will the Supreme Court Limit Nanotech Patents?
Stephen B. Maebius, June 4, 2013
In a case styled The Association for Molecular Pathology v. Myriad Genetics, the Supreme Court is confronting the question of whether or not human genes are patent eligible under 35 U.S.C. 101. A decision is expected in the near future. A primary argument of the parties opposing gene patents is...

Return to the Foley & Lardner LLP Firm Overview